Al
Not verified

Alnylam Pharmaceuticals, Inc.

What we write about

BiotechnologyHealthMedicine - variousPharmaceuticalsWEB AND SOCIAL NETWORK
09/06/2025
Scienza
Cardiology
Biotechnology
Pharmaceuticals
Health
Medicine - various
Labour market
Industria
Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy
1.00
28/05/2025
Biotechnology
Pharmaceuticals
Health
Sanità
Eventi
WEB AND SOCIAL NETWORK
Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference
1.00
20/05/2025
Responsabilità sociale d'impresa
Industria
Health
Medicine - various
Scienza
Pharmaceuticals
Biotechnology
Alnylam Issues 2024 Corporate Responsibility Report
1.00
05/05/2025
Eventi
WEB AND SOCIAL NETWORK
Biotechnology
Pharmaceuticals
Health
Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference
1.00
01/05/2025
WEB AND SOCIAL NETWORK
Phones and Miscellaneous
stock market
Biotechnology
Food hygiene
Health
Pharmaceuticals
Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress
1.00
28/04/2025
Industria
Cardiology
Biotechnology
Food hygiene
Health
Sanità
Pharmaceuticals
Scienza
Medicine - various
Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
1.00
17/04/2025
WEB AND SOCIAL NETWORK
Phones and Miscellaneous
Finance
stock market
Biotechnology
Pharmaceuticals
Health
Sanità
Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results
1.00
01/04/2025
Eventi
WEB AND SOCIAL NETWORK
Biotechnology
Pharmaceuticals
Health
Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference
1.00

Contact details

Social Media

Followers
0
Compatibility
0